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ABSTRACT
The influenza pandemic that emerged in 2009 provided an unprecedented opportunity to study adaptation of a virus recently
acquired from an animal source during human transmission. In the United Kingdom, the novel virus spread in three temporally
distinct waves between 2009 and 2011. Phylogenetic analysis of complete viral genomes showed that mutations accumulated
over time. Second- and third-wave viruses replicated more rapidly in human airway epithelial (HAE) cells than did the first-wave
virus. In infected mice, weight loss varied between viral isolates from the same wave but showed no distinct pattern with wave
and did not correlate with viral load in the mouse lungs or severity of disease in the human donor. However, second- and third-
wave viruses induced less alpha interferon in the infected mouse lungs. NS1 protein, an interferon antagonist, had accumulated
several mutations in second- and third-wave viruses. Recombinant viruses with the third-wave NS gene induced less interferon
in human cells, but this alone did not account for increased virus fitness in HAE cells. Mutations in HA and NA genes in third-
wave viruses caused increased binding to -2,6-sialic acid and enhanced infectivity in human mucus. A recombinant virus with
these two segments replicated more efficiently in HAE cells. A mutation in PA (N321K) enhanced polymerase activity of third-
wave viruses and also provided a replicative advantage in HAE cells. Therefore, multiple mutations allowed incremental changes
in viral fitness, which together may have contributed to the apparent increase in severity of A(H1N1)pdm09 influenza virus dur-
ing successive waves.
IMPORTANCE
Although most people infected with the 2009 pandemic influenza virus had mild or unapparent symptoms, some suffered severe
and devastating disease. The reasons for this variability were unknown, but the numbers of severe cases increased during succes-
sive waves of human infection in the United Kingdom. To determine the causes of this variation, we studied genetic changes in
virus isolates from individual hospitalized patients. There were no consistent differences between these viruses and those circu-
lating in the community, but we found multiple evolutionary changes that in combination over time increased the virus’s ability
to infect human cells. These adaptations may explain the remarkable ability of A(H1N1)pdm09 virus to continue to circulate
despite widespread immunity and the apparent increase in severity of influenza over successive waves of infection.
In 2009, a novel H1N1 influenza virus [A(H1N1)pdm09] crossedthe species barrier from swine into humans, causing the first
influenza pandemic of the 21st century. The swine-origin virus
displayed a complex genotype, including antigen gene segments
derived from swine-adapted influenza viruses that had previously
circulated on different continents and an internal gene cassette
known as the triple-reassortant genotype (TRIG), first described
in pigs in the late 1990s (1–3). The TRIG cassette contained two
polymerase components, PB2 and PA, from an avian virus and the
other, PB1, from a human-adapted virus. The NP, HA, and NS
gene segments of the pandemic H1N1 2009 virus were acquired
from the classical swine virus lineage that has circulated in pigs
since 1918 and had been maintained in North American swine
viruses (4, 5). Classical swine influenza viruses shared an origin
with the human H1N1 seasonal influenza viruses, but the two had
since undergone species-specific mutations in their respective
hosts. The genetic distance between the HA genes was sufficient to
cause a pandemic, despite the circulation of seasonal H1 viruses in
humans from 1977 until 2009. The A(H1N1)pdm09 NP gene had
adaptations associated with evasion of MxA from swine or hu-
mans (6). Finally, RNA segment 8, encoding NS1 and NEP pro-
teins, had accumulated many mutations that differentiated it from
the NS segment of human-adapted influenza viruses. Notably, the
swine virus NS1 protein had become truncated through a termi-
nation codon at amino acid 220 in comparison to the human-
adapted NS1 protein, which retained a typical NS1 length of 230
residues (5). A functional difference in the swine-origin NS1 was
reported by Hale et al. (7) and confirmed by us (8), whereby the
ability to bind to the human host cell factor CPSF 30 and limit host
gene expression had been lost by the accumulation of at least 3
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mutations in the C-terminal domain of the NS1 gene. Thus, the
virus that crossed from pigs to humans and sparked the 2009
pandemic was not optimized for human replication and transmis-
sion because its gene segments were swine adapted.
In the United Kingdom, there were two waves of A(H1N1)
pdm09 activity during the 2009-2010 pandemic period: an ini-
tial out-of-season outbreak that started in April 2009 and
peaked in July 2009, followed by a second wave in the autumn
and winter of 2009-2010. In the first postpandemic winter
(2010-2011), a third wave of A(H1N1)pdm09 activity was seen.
This third wave was associated with an increase in infection and
severity and a shift in age demographics from children (0 to 15
years old) and younger adults (16 to 44 years old) to predom-
inantly adults (9–12). Compared with the first two pandemic
waves, the third wave was associated with more hospital admis-
sions (8,797 versus 7,879 people), more people admitted to
critical care (2,200 versus 1,700 people), and a greater number
of deaths (474 versus 361 people) in England (13). Although
there had been evidence of sequence variation in viruses in the
second pandemic wave in the United Kingdom and elsewhere
(14, 15), surveillance and antigenicity studies had reported no
change in the antigenicity of the surface glycoproteins hemag-
glutinin (HA) and neuraminidase (NA), so a vaccine update
was not warranted (14). Moreover, any change in antigenicity
would be unlikely to explain the increased severity of third-
wave viruses in the unvaccinated or those who had not previ-
ously contracted the virus. Nonetheless, it is possible that other
genetic changes distinct from those with an antigenic effect
may have led to increased circulation of the virus or enhanced
virulence that accounted for the apparent increased severity in
the United Kingdom’s third wave. Indeed, Dorigatti and Fer-
guson recently modeled the United Kingdom third wave and
concluded that the observed increased numbers of cases were
most likely accounted for by an increase in virus transmission
with a commensurate increase in the numbers of severely ill.
They suggested this could be due to weather conditions, as that
winter was particularly cold and dry and favored virus trans-
mission events, or to a change in the inherent transmissibility
of the virus itself, or both (16). Here we report genetic variabil-
ity across the three waves of influenza virus A(H1N1)pdm09 in
the United Kingdom and identify nonsynonymous variants
that define the third-wave viruses. We show that mutations in
HA and NA, the PA component of the polymerase complex,
and the NS1 interferon (IFN) antagonist protein enhanced the
virus’ ability to replicate in human airway cells.
MATERIALS AND METHODS
Cells. Madin-Darby canine kidney (MDCK), human embryonic kidney
(293T), and newborn pig tracheal (NPTr) cells were grown in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal calf se-
rum (FCS). MucilAir cultures of human nasal epithelium (HAE; Epithe-
lix) were grown in MucilAir medium. All cells were maintained at 37°C in
5% CO2.
Patient recruitment and sampling. The MOSAIC study investigators
recruited adult and pediatric patients admitted to the hospital with sus-
pected influenza virus infection in London and Liverpool between De-
cember 2009 and February 2011. Infection with seasonal influenza A
H3N2, influenza B, or A(H1N1)pdm09 viruses was confirmed locally by
viral PCR according to regional protocols. Patients were approached for
recruitment and initial (T1) sampling as soon as possible following ad-
mission to a MOSAIC-associated hospital. Nasopharyngeal aspirate
(NPA) and viral throat swab samples were obtained according to the study
standard operating procedures. Patients with comorbidities were not ex-
cluded. Different severities of illness were included, and severity was
graded as follows: grade 1, no respiratory compromise (oxygen saturation
of 93% on room air); grade 2, respiratory compromise requiring non-
invasive oxygen supplementation; grade 3, respiratory compromise re-
quiring invasive mechanical ventilation and oxygen supplementation.
The MOSAIC study was approved by the NHS National Research Ethics
Service, Outer West London REC (09/H0709/52 and 09/MRE00/67).
Viruses. Influenza viruses were isolated from clinical specimens by the
Respiratory Virus Unit, Public Health England (PHE), Colindale, Lon-
don. Briefly, clinical specimens, including NPA, viral throat swab in virus
transport medium (VTM), bronchial alveolar lavage (BAL) fluid, or en-
dotracheal aspirate (ETA), were transported to PHE frozen on dry ice. For
virus isolation, 200-l clinical specimen aliquots were inoculated onto
monolayers of MDCK cells or the SIAT-1 cell derivative in virus isolation
tubes and allowed to adsorb for 1 h (17). Cells were incubated in serum-
free Earles minimal essential medium in the presence of 1.25 g/ml tosyl-
sulfonyl phenylalanyl chloromethyl keton (TPCK)-treated trypsin (Wor-
thington) on a rolling drum at 33°C for a maximum of 7 days with regular
observation for viral cytopathic effect (CPE). Blind passage on fresh cells
for a further 7 days was performed where necessary. Virus growth was
determined by hemagglutination assay using turkey or guinea pig red
blood cells. One further virus passage was made to generate a large stock of
virus for distribution to the MOSAIC group.
Plasmid-based reverse genetics. The reverse genetics viruses were
generated as previously described (8) from plasmids either synthesized
(GeneArt) from the A/England/195/2009 whole-genome sequence and
A/England/687/2010 segment 4 sequence or generated by site-directed
mutagenesis (Stratagene Lightening mutagenesis kit) of A/England/195/
2009 plasmid sequence with the point mutations necessary to create the
A/England/687/2010 amino acid sequence. The plasmids were sequenced
to confirm the presence of the required mutations and absence of un-
wanted variations. Primer sequences are available upon request. Reverse
genetics viruses were generated using the 12-plasmid system with either
A/England/195/2009 or A/England/687/2010 polymerase I clones and
helper polymerase of A/Victoria/3/75.
Virus replication in cell lines and primary airway cultures. Conflu-
ent cell monolayers were infected with equal PFU of each virus at a mul-
tiplicity of infection (MOI) of 0.01 or 0.001 as indicated below. The cells
were incubated in the inoculum for 1 h, and then the inoculum was re-
moved, cells were washed with phosphate-buffered saline (PBS), overlaid
with DMEM supplemented with nonessential amino acids, penicillin-
streptomycin, and TPCK-treated trypsin, and incubated at 34°C in 5%
CO2. Growth was assessed by well sampling at fixed time points and titra-
tion on MDCK cells by plaque assay. For infection of MucilAir cultures,
the apical surface (air interface) was washed with serum-free (SF) medium
prior to infection, then washed again after the inoculation. Viral titer was
assessed by sampling from the apical surface by the addition of 200 l of
serum-free medium, incubation for 15 min, and removal of the medium.
The basal layer was sampled for cytokine analysis, with an equal volume of
MucilAir medium replacing that removed.
Virus competition assays. Cells in MucilAir were washed with serum-
free DMEM prior to inoculation with a 50:50 mix of two viruses at a total
MOI of 0.001. The cells were incubated for 1 h prior to removal of the
inoculum and washing with SF medium. The apical layer was sampled
every 12 h as described above. Viral RNA was extracted from the super-
natant with a Qiagen Qiamp vRNA kit and processed for Ilumina deep
sequencing. Each assay was run in triplicate.
Minigenome polymerase assays. The coding sequences for the PB1,
PB2, PA, and NP proteins were amplified using KOD polymerase (Nova-
gen) and primers containing restriction sites to allow incorporation into
pCAGGs expression vectors. To introduce alternative amino acids into
the coding sequence, site-directed mutagenesis was undertaken on the
reverse genetic genomic plasmids. Primers are available on request.
Elderfield et al.
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pCAGGs expression plasmids for PB1, PB2, PA, and NP proteins were
transfected onto a confluent layer of 293T cells by using Lipofectamine
2000 and Optimem in a plasmid concentration ratio of 1:1:0.5:2, respec-
tively. Additionally, a plasmid encoding a minigenome firefly luciferase
reporter flanked by the promoter region of the influenza virus segment 8
and either a Renilla or -galactosidase transfection control plasmid were
cotransfected with the minigenome complement. Cells were incubated
with the transfection mix for 24 h at 34°C at 5% CO2. Then, supernatant
was removed, the cells were washed, and 100 l of passive lysis buffer was
added (Promega). The cells were freeze-thawed, and lysates were analyzed
with the dual luciferase reporter system (Promega) on the FLUOstar
Omega system (BMG Labtec). All assays were run in triplicate, with each
assay being repeated a minimum of 3 times.
Interferon reporter assays. A plasmid with the beta interferon pro-
moter region upstream of a firefly luciferase reporter was transfected
along with a -galactosidase or Renilla control plasmid into 293T cells in
suspension by using Lipofectamine 2000 and Optimem. 293T cells were
allowed to adhere to plates pretreated with poly-L-lysine and incubated
overnight. The cells were then infected with virus at an MOI of 3 and
incubated at 37°C for 1 h prior to inoculum removal, washing, and over-
laying with DMEM with 10% FCS. The cells were then harvested at set
time points by the removal of medium, washing with PBS, the addition
of passive lysis buffer, and passage through a freeze-thaw cycle prior to
detection with the dual luciferase reporter system (Promega) on the
FLUOstar Omega apparatus (BMG Labtec). All assays were run in tripli-
cate, with each assay being repeated a minimum of 3 times.
Mouse experiments. All animal procedures and care conformed
strictly to the United Kingdom Home Office Guidelines under the Ani-
mals (Scientific Procedures) Act 1986, and the protocols were approved
by the Home Office of Great Britain (license number 70/6646).
Fifteen weight-matched female BALB/c mice anesthetized with isoflu-
rane were inoculated with 7.5  105 or 2  105 PFU of each influenza
virus. Mice were weighed daily, and any mice falling below a 30% weight
loss threshold were sacrificed. At day 2 and day 4 postinfection, 5 mice
from each experimental group were sacrificed and the lungs harvested.
Whole lungs were weighed and homogenized in the presence of 1 ml of
PBS and split into aliquots. An aliquot of lung homogenate from each
mouse was subjected to titration by plaque assay. Results are expressed in
milliliters of the homogenate, as whole mouse lungs were homogenized in
a standardized volume of PBS.
Interferon detection. Aliquots of mouse lung homogenate were tested
for the presence of mouse interferon by using the Verikine alpha inter-
feron kit (R&D Systems) according to the manufacturer’s instructions
and then measured on the FLUOstar Omega system (BMG Labtec). Each
sample was run in duplicate.
Phylogenetic analysis. Complete genomes of samples sequenced by
the MOSAIC group were aligned against all complete A/H1N1/09 ge-
nomes up to 2011 that were present in the NCBI Influenza Virus Resource
database (18). To improve tree readability, this set of 2,084 genomes was
down-sampled by using custom Python scripts, ensuring that the topol-
ogy of the phylogenetic tree was maintained. Phylogenetic trees were in-
ferred by using a neighbor-joining clustering method with branch lengths
and substitution parameters estimated using the Tamura-Nei model un-
der the maximum composite likelihood method implemented in MEGA
version 6.06 (19). Tree robustness was evaluated by bootstrapping with
1,000 pseudoreplicates.
Statistical analysis. All statistical analyses were conducted using
GraphPad Prism software. Virus replication, IP-10, IFN cytokine produc-
tion, and mucus inhibition assays were assessed by unpaired t tests com-
pared to the A/195 first-wave isolate. The interferon and minigenome
assays were assessed by repeated-measures or ordinary one-way analysis
of variance (ANOVA) with Tukey’s multiple-comparison test, as appro-
priate.
RESULTS
The Mechanisms of Severe Acute Influenza Consortium (MOSAIC)
was formed to investigate why some individuals infected by the
pandemic H1N1 influenza virus developed severe symptoms re-
quiring hospitalization while others developed a milder coryzal
illness. MOSAIC recruited 85 patients admitted to the hospital
with influenza-like illness in the winter of 2009-2010 and a further
172 patients in the winter of 2010-2011. NPA and viral throat swab
specimens were collected from patients for attempted isolation of
virus strains by culture in MDCK cells, assessment of viral titer by
quantitative reverse transcription-PCR (qRT-PCR), and whole-
genome sequencing directly from the clinical sample.
Evolution of influenza A(H1N1)pdm09 viruses showed a dis-
tinct United Kingdom third-wave lineage. Clinical samples, ei-
ther NPA or throat swabs that were positive for influenza
A(H1N1)pdm09 RNA, were prepared without virus isolation or
passage and sequenced by using either the Roche Genome Se-
quence FLX 454 or Illumina Genome Analyzer IIx platforms as
previously described (20) and assembled into full genomes as de-
scribed elsewhere (21). Background whole-genome pandemic se-
quences were downloaded from NCBI’s Influenza Virus Resource
database (18) and aligned against the United Kingdom first-, sec-
ond-, and third-wave genomes. Phylogenetic analysis showed that
viruses from the first two pandemic waves were closely related,
consistent with the proposed persistence of the first-wave lineages
into the second wave in the United Kingdom (20). However, vi-
ruses detected during the third wave (winter of 2010-2011) were
genetically distinct, with the majority of genomes clustering in a
separate monophyletic clade (Fig. 1). Across the second and third
waves in the United Kingdom, viruses from hospitalized patients
were phylogenetically indistinguishable from community and
nonhospitalized control patients and did not contain shared ge-
nome variants that could confer enhanced pathogenicity (Fig. 1).
We assessed amino acid changes fixed in the majority of viruses
and identified 21 common changes across all segments, of which
12 were unique to third-wave viruses (Table 1). These changes also
accumulated in second- and third-wave virus isolates from other
regions of the United Kingdom and from the rest of the world
(Table 2), except for G189D in NS1. We also checked for nucleo-
tide differences in segment 2 that would affect the translation of
PB1-F2 and/or N40 open reading frames, but we found none.
Clinical isolates from the first, second, and third pandemic
waves varied in their growth kinetics in primary human airway
cultures. The lack of a common genetic difference between influ-
enza viruses isolated from severe or mild influenza cases in each
wave suggests that the observed increase in overall severity in the
third wave may be related to a general property of third-wave
viruses, which should be reflected in virological differences be-
tween first-, second-, and third-wave viruses.
To assess virus differences, we isolated virus from clinical
samples in SIAT-MDCK cells for a subset of viruses selected in
accordance with their placements on the phylogenetic tree in
Fig. 1. We infected MDCK cells or primary HAE cultures or
mice with 9 different clinical isolates from the second wave (3
viruses) and the third wave (6 viruses), and we compared
growth and outcome of infection with the first-wave prototypic
United Kingdom A(H1N1)pdm09 virus, A/England/195/2009.
Clinical data for patients from whom these isolates were ob-
tained are shown in Table 3. We recorded the differences in
Human Adaptation of A(H1N1)pdm09 during Pandemic Waves
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viral RNA load in NPA at time of recruitment (T1 NPA titer),
the severity score for the patient, and the presence of patient
comorbidities. With the caveat that the delay between symp-
tom onset and recruitment varied from patient to patient (day
since symptom onset), we did not find any correlation between
viral load and severity score for this subset of the MOSAIC
cohort.
In vitro, first-, second-, and third-wave viruses used to infect
MDCK cells did not show a consistent difference in replication pat-
tern according to respective waves, although there were small varia-
tions between individual isolates (Fig. 2A). In HAE cell cultures, the
patterns of virus replication were more diverse and correlated with
respective waves. Although two viruses, one from the second wave
(A/47) and one from the third wave (A/213), displayed similar
growth kinetics to the prototypic A/195 virus, most second- and
third-wave viruses displayed a growth advantage at 24 and 48 h
postinfection in human airway cells. Using a different HAE culture
code (primary cells obtained from a different donor), a representative
third-wave clinical isolate, A/687, displayed a consistent 2-log10
growth advantage at the 24- and 48-h time points, with a peak titer of
108 PFU/ml, compared with 106 PFU/ml for the A/195 first-wave
virus at 48 h postinfection (P  0.02), before the virus titers became
similar at 72 h postinfection (Fig. 2c). Strikingly, in pig tracheal cell
cultures (NPTr), the third-wave virus A/687 was compromised in
growth (Fig. 2c). In other human lung cell lines, such as Calu-3, the
first-wave virus also replicated more efficiently than the third-wave
virus, although the difference was not as pronounced as in the pig cell
line. This suggests that the adaptation in third-wave virus might be
conferred by features only present in the well-differentiated complex
HAE cultures.
FIG 1 Phylogenetic relationship of complete influenza A(H1N1)pdm09 virus genomes. The tree is rooted on A/California/04/2009, shown as a blue-filled circle.
United Kingdom first-wave isolates are highlighted as blue circles, while isolates sequenced by MOSAIC are shown as red circles for second-wave isolates from
community and hospitalized patients, and green circles show isolates from third-wave community and hospitalized patients. Isolates characterized in this study
are indicated with colored arrows, while the inferred ancestral location of the asparagine-lysine mutation in PA is indicated with a black arrow. Nodes with
bootstrap support of 75% are highlighted with asterisks. Bar, 0.002 substitutions/site.
Elderfield et al.
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Outcomes of infection in the in vivo BALB/c mouse model
did not correlate with patient severity or growth in human air-
way cultures. In order to assess the in vivo characteristics of this
panel of clinical isolates, we utilized a mouse model. BALB/c mice
were infected intranasally with each of the panel of viruses. After a
dose of 2  105 PFU, the A/195 first-wave isolate caused 20%
weight loss by day 5 postinfection (Fig. 3a). Some of the second-
and third-wave viruses inoculated at the same dose were less
pathogenic in mice, as ascertained by less weight loss; for example,
the A/687 third-wave virus induced only 2% weight loss and no
mortality (Fig. 3b and c). Mouse mortality (due to humane cull
based on weight loss) was observed in all three of the sets of mice
infected with the second-wave viruses but only in two sets (A/689
and A/672) of the third-wave virus-infected mice. Statistically,
only the A/09-infected mice did not show a difference in weight
loss compared to the A/195-infected mice; the A/47 and the A/689
mouse groups displayed a statistical difference only on days 2 and
3, respectively. The differences in weight loss and mortality in
mice did not correlate with the severity scores assigned to the
human patients infected with the same virus (Fig. 3a, b, and c and
Table 3). Interestingly, the viral loads in the mouse lungs at day 2
or 4 postinfection did not show the same pattern as titers in HAE
culture infections, with a trend toward lower virus lung titers at
day 2 for the second- and third-wave viruses compared to A/195
(Fig. 3d). For example, the first-wave A/195 virus replicated to
high levels in mice, whereas the third-wave A/687 virus replicated
comparatively poorly, but in HAE cells the situation was reversed
(Fig. 2c). However, in some cases the reciprocal pattern between
HAE replication and mouse pathogenicity was not maintained:
A/672, which had similar growth in HAE as A/687, replicated to a
higher titer, induced greater weight loss of around 15%, and led to
20% mouse mortality. There are only four coding genetic differ-
ences between these two third-wave viruses: HA L176I, NS1
I123V, PB1 I12T, and PB2 N556S.
The most obvious trait that was associated with virus wave was a
clear association between the IFN- level in the mouse lung and the
wave of isolation for each virus; levels of IFN in lungs of mice infected
with second-wave viruses were lower than for A/195, and the lowest
IFN levels were in third-wave virus-infected mouse lungs (Fig. 3e).
The lower IFN production as the waves progressed could reflect the
virus adapting to better control the host immune system. The same
patterns of weight loss, lung titers, and lung interferon levels for each
isolate were observed in a separate experiment in which mice were
infected with 7.5  105 PFU (data not shown).
Virus with segment 8 of the third-wave virus induced less
type I interferon. The increased interferon in lungs of mice in-
TABLE 1 Amino acid changes observed in 10 A/H1N1 pdm(2009) viruses isolated in the United Kingdom, in comparison to prototypic virus
A/England/195/2009a
a Data for the three isolates from the 2009-2010 season are above the line, and data for the 6 isolates from 2010-2011 are below it.
Human Adaptation of A(H1N1)pdm09 during Pandemic Waves
November 2014 Volume 88 Number 22 jvi.asm.org 13273
 o
n
 April 12, 2016 by Univ of Nottingham
http://jvi.asm.org/
D
ow
nloaded from
 
fected with first-wave virus might be driven by higher viral loads.
However, viral loads in lungs at day 2 were not always higher in
mice infected by second-wave versus third-wave viruses, but IFN
levels were higher (Fig. 3d and e). We hypothesized that mutations
in the virus between the second and third waves may have en-
hanced the virus’ ability to control the innate immune response.
NS1 protein encoded on RNA segment 8 is the major interferon
antagonist of influenza A virus. Sequence analysis showed third-
wave viruses possessed a cluster of amino acid changes in the NS1
protein in various combinations at positions E55Q, P114T, I123V,
and G189D (Table 1). A third-wave isolate, A/687, possessed three
of these changes within the effector domain of the NS1 protein:
114T, 123V, and 189D. The G189D variation also changed the
coding sequence of the NEP protein (V32I), because the NS1 and
NEP open reading frames overlap at this region. Under the con-
ditions used for these assays, IFN- was undetectable in apical
washes or in basal medium from infected HAE cultures. There-
fore, we assessed the virus’ ability to counteract the production of
an innate induced cytokine, IP-10. At 16 h postinfection with a
high multiplicity of virus, significantly less IP-10 was secreted
from HAE cells infected with the A/687 virus than cells infected
with the first-wave virus A/195 (Fig. 4a). Levels of two other cyto-
kines, interleukin-6 (IL-6) and IL-8, were also lower in basolateral
media following infection of the HAE cells with third-wave virus
(data not shown), but the difference did not reach significance.
IFN was not detectable in samples collected from the HAE cells
after infection with either virus.
To further assess the role of the NS gene mutations in control-
ling the cytokine response, we generated recombinant viruses with
the segment 8 RNAs exchanged. The A/195 reverse genetics (RG)
system described previously was generated by synthesizing the
cDNAs for this strain de novo (8, 22). The A/687 reverse genetics
virus was created by site-directed mutagenesis of the A/195 plas-
mids wherever an amino acid change was present, for seven of the
gene segments. The gene segment encoding the A/687 HA was
synthesized de novo.
293T cells transiently transfected with an IFN- promoter
luciferase reporter construct were infected with each of the 7:1
single-gene reassortant viruses or with the isogenic A/195 or
A/687 wild-type RG viruses (Fig. 4b) (23). The A/687 RG virus
TABLE 2 Prevalence ratios of amino acid changes in influenza viruses in the United Kingdom and the rest of the world (RoW) during the first,
second, and third waves of virus infection
a Incomplete ratios are due to unknown or multiple minor populations. HA numbering is based on that of H1.
Elderfield et al.
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induced a significantly lower luciferase signal than A/195. The
induction of the IFN- promoter was decreased relative to that
with the isogenic A/195 virus when the 687 NS gene was present
and significantly increased for the A/687 virus with A/195 NS.
Since there was also a difference in NEP coding between these
two viruses, we tested whether the NS1 protein itself had altered
activity as an interferon antagonist when expressed exogenously.
At 3 different doses of NS1 expression, the third-wave NS1 protein
TABLE 3 Patient information for the MOSAIC viral isolates
Isolate
Severity
scorea Comorbiditiesb
Collection date
(mo-yr)c
Days since
symptoms onsetd Virus detectione
T1 NPA titerf
(PFU/ml)
A/England/195/2009 Mild NKg Apr-09 NK NK NK
A/England/06/2010 1 Yes Jan-10 20 NPA 5,802
A/England/09/2010 1 Yes Dec-09 2 NPA 7,035
A/England/47/2010 3 Yes Dec-09 9 NPA, blood, stool 2,315
A/England/213/2011 2 Yes Jan-11 1 NPA 47
A/England/672/2010 2 Yes Dec-10 4 NPA 0.2
A/England/675/2010 1 No Dec-10 2 NPA 2
A/England/687/2010 2 Yes Dec-10 2 NPA 8
A/England/689/2010 1 Yes Dec-10 2 NPA 1,251
A/England/699/2010 3 Yes Dec-10 4 NPA 23
a The severity score was assigned according to the severity of respiratory impairment, as follows: grade 1, no respiratory compromise (oxygen saturation of 93% on room air);
grade 2, respiratory compromise requiring noninvasive oxygen supplementation; grade 3, respiratory compromise requiring invasive mechanical ventilation and oxygen
supplementation.
b Predisposing (comorbid) conditions included asthma, immunosuppression, etc. NK, not known.
c The month the sample (from which the virus was isolated) was collected.
d The time between onset of symptoms and viral sample collection.
e Sample types in which virus was detected. NPA, nasopharyngeal aspirate.
f The viral titer was assessed by qPCR of the H1N1 NA gene and compared against a standard curve of viral RNA of known PFU/ml.
g NK, not known.
FIG 2 Replication of A(H1N1)pdm09 viruses in cell culture. (a and b) Viral growth of 10 clinical isolates from first-wave (blue), second-wave (red), or
third-wave (green) viruses in MDCK cells (a) and human nasal MucilAir cell cultures (HAE; Epithelix) (b). Cells were infected at an MOI of 0.001 (MDCK cells)
or 0.01 (MucilAir) and incubated at 34°C. The dashed line represents the mean for A/195. Statistics in the tables adjoining the chart keys were calculated using
unpaired t tests with Holm-Sidak corrections. (c) Replication of a representative first-wave (A/195; blue circles) and third-wave (A/687; green squares) virus pair
was assessed in HAE cells (left panel), MDCK cells (left middle panel), CALU3 cells (right middle panel), and pig tracheal cells (right panel). Cells were infected
at an MOI of 0.001. Statistics were calculated using unpaired t tests.
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was significantly better able to control the expression of luciferase
driven by an interferon promoter in Newcastle disease virus
(NDV)-infected cells (Fig. 4c).
The HA and NA genes of third-wave viruses displayed differ-
ent receptor binding preferences, enhanced infectivity in hu-
man mucus, and conferred enhanced growth in HAE cell cul-
tures compared to first-wave viruses. Second- and third-wave
United Kingdom viruses displayed wave-associated amino acid
changes in the HA and NA proteins (Table 1). A collection of 11
MOSAIC virus isolates representative of the three waves, includ-
ing A/195 (first wave), A/06 (second wave), and A/675 and A/687
(third wave) from the panel of nine viruses studied above, were
tested in a hemagglutination assay using erythrocytes from differ-
ent species (guinea pig, turkey, and chicken), which are known to
differ in specificity and density of sialic acids expressed on their
cell surfaces (24). All viruses displayed comparable binding to
guinea pig and turkey erythrocytes, but the second- and third-
wave isolates displayed lower binding to chicken red blood cells
FIG 3 Infection of mice with A(H1N1)pdm09 viruses. (a to c) Weight loss was followed after infection of 15 BALB/c mice inoculated intranasally with 2  105
PFU of virus isolates: (a) one A/195 first-wave isolate (blue); (b) three second-wave isolates (red); (c) six third-wave isolates (green). Weights in mice inoculated
with PBS are shown in black. (d and e) Virus titers (d) and interferon levels (e) in lung homogenates at day 2. (f) Mouse mortality data for virus infections where
weight loss necessitated culling.
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relative to A/195 (Fig. 5a). The only exception was A/675, which
has an M227I (230 in H3 numbering) amino acid variation near
the receptor binding pocket and retained strong binding to
chicken erythrocytes. HA assays performed with RG A/195 and
A/687 viruses recapitulated the general pattern seen for the panel
of isolates; the relative binding of the first-wave virus for chicken
erythrocytes was higher than for the third-wave virus (Fig. 5b).
A/687 virus differs from A/195 by 8 amino acids in the HA
protein and 4 in the NA protein. To test if the changes in HA and
NA alone were sufficient to confer the observed growth advantage
in human airway cells (Fig. 2b and c), we generated 6:2 recombi-
nant viruses with the A/687 HA and NA combined with A/195
internal proteins or the A/687 internal genes with the HA and NA
of A/195, and we compared their replication with that of isogenic
wild-type RG A/195 or RG A/687. The virus with the A/687 inter-
nal genes coupled with first-wave HA and NA replicated to a lower
titer than whole A/687 virus, and conversely, the virus with A195
internal genes and third-wave HA and NA replicated to higher
titers than whole A/195 virus. However, the differences in replica-
tion did not reach statistical significance (Fig. 5c). This suggests
that both internal and external genes contribute to the enhanced
replication of third-wave virus in HAE cultures, but neither of the
gene sets is sufficient to reproduce the phenotype alone.
To investigate a role for the third-wave NA protein in en-
hanced replication in HAE cultures, we generated a 7:1 RG virus
with 7 segments from the A/195 virus and RNA segment 6, which
encodes the NA protein from A/687. This virus and the isogenic
A/195 virus were then incubated in the presence of human respi-
ratory mucus for 60 min prior to infection of MDCK cells. The
numbers of plaque-forming foci were counted, and the percent
reduction in infectivity was calculated (25). The virus carrying the
third-wave NA gene segment displayed an increased ability (P 
0.044) to overcome inhibition of infectivity by human mucus,
which is an important factor in the ability of a virus to infect and
spread in the human airway (Fig. 5d).
The mutation in PA N321K of third-wave viruses conferred
enhanced replication in a minireplicon assay and in viral com-
petition assays. Mutations in other genes of the second- and
third-wave viruses may have also contributed to human adapta-
tion and enhanced replication in HAE cells. In the polymerase
proteins and nucleoprotein of the A/687 virus, there were 7 amino
acid changes from A/195 polymerase genes, 3 of which were
unique to the majority of the third-wave viruses in the United
Kingdom. These three changes were at PB2 V344M, I354L, and PA
N321K (Table 1).
In order to assess whether these amino acid changes altered the
activity of the viral polymerase, we created two sets of expression
plasmids that allowed reconstitution of polymerase components
from either A/195 or from A/687 virus. For the A/195 constella-
tion, we used a PA plasmid with the glycine 3 mutated to aspartic
FIG 4 Cytokine induction by first- and third-wave viruses and the role of NS gene segments in virus replication in HAE cells. (a) Human nasal MucilAir cell
cultures (HAE; Epithelix) were infected in triplicate with RG A/195 and A/687 virus at an MOI of 1 for 16 h. The basal medium was harvested, and levels of the
cytokine IP-10 were measured using mesoscale discovery (MSD) plates. Statistical analysis was performed with an unpaired t test. (b) 293T cells transiently
transfected with a beta interferon promoter luciferase reporter plasmid were infected with RG viruses A/195 (dark blue), A/195 with A/687 segment 8 (light
green), A/687 (dark green), and A/687 with the A/195 segment 8 (light blue) at an MOI of 3. Infection with NDV was used as a positive control. Statistical analysis
entailed a one-way ANOVA, with Tukey’s multiple-comparison test (and associated adjusted P values). (c) 293T cells transiently transfected with an beta
interferon promoter luciferase reporter and pCAGGs NS1 plasmids A/195 (blue), A/687 (green), and H3N2 (purple). Positive controls were stimulated with
NDV. Statistical analysis was performed with a one-way ANOVA and Tukey’s multiple-comparison test.
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acid, since this difference was atypical among first-wave viruses
(17). Each viral polymerase was reconstituted in a minireplicon
reporter assay in 293T cells as previously described (26). The
third-wave A/687 polymerase and nucleoprotein complex consis-
tently directed higher amplification and higher expression of the
luciferase signal from the minireplicon in human cells than the
A/195 polymerase constellation (P  0.001) (Fig. 6a).
In order to discern if this enhancement of polymerase activity
was a result of amino acid changes in a single protein, the minire-
plicon assays were carried out with single protein exchanges. A
dramatic 10-fold decrease in signal was observed when the A/195
PA protein was paired with the A/687 PB1, PB2, and NP proteins.
The reciprocal exchange showed the converse result, although the
increase in polymerase activity when A/687 PA was introduced
into the A/195 polymerase constellation was not statistically sig-
nificant (Fig. 6a).
To assess whether the PA N321K mutation led to an enhance-
ment of replication in the context of whole virus, we generated a
7:1 (PA) RG virus in which every genomic segment except for the
A/687 PA segment was derived from A/195. Replication competi-
tion experiments starting with a 50:50 mix in triplicate HAE cul-
tures were analyzed by deep sequencing using Illumina sequenc-
ing technology and showed the virus with the PA 321K from the
third-wave genotype rapidly dominated the viral RNA population
in all 3 biological replicates (P  0.0078, 0.0001, and 0.0001 at
48, 72, and 96 h, respectively, when assessed as the percentage of
total reads via an unpaired t test), illustrating a growth advantage
in human cells conferred by this amino acid change (Fig. 6b).
DISCUSSION
In the United Kingdom, there was a reported increase in severity
of the pandemic H1N1 virus as the waves of influenza virus infec-
tion progressed from its emergence in spring 2009 until the end of
winter 2011 (10, 12). It has been suggested that this can be attrib-
uted to a shift in the behavior of the infected population due to a
change in public health responses (10, 13). However, this expla-
nation does not exclude host adaptations in the influenza virus
itself that might also have contributed to the change in severity
associated with A(H1N1)pdm09 infection. If the virus were re-
sponsible, there may have been a specific virulence factor that
appeared in many or all of the hospitalized cases; however, we
found no evidence for this in our study. We can discern from
whole-genome sequence data provided by FLUWatch, FF100,
PHE, RCGP, and the isolates derived from the hospitalized
MOSAIC patients over three waves of infection in the United
Kingdom that the viruses derived from hospitalized patients did
not vary genetically from those found within the community, con-
sistent with the findings of Galliano et al. for the second wave (27).
Alternatively, a constellation of adaptive changes that accumu-
lated in the virus as it circulated in the community could have
made it more likely that a higher proportion of individuals would
FIG 5 Variation in surface genes HA and NA in third-wave virus isolates leads to altered receptor binding, enhanced replication in HAE cells, and enhanced
infectivity in mucus. (a) Hemagglutination assay with 11 clinical isolates from first-wave (blue), second-wave (red), and third-wave (green) isolates, assessed for
binding to 0.5% chicken, turkey, or guinea pig red blood cells. The dashed line represents the A195 HA score. (b) Hemagglutination assay with equal PFU of
A/195 first-wave (blue) and A/687 third-wave (green) RG viruses with 0.5% chicken or turkey red blood cells. (c) Viral replication in human nasal MucilAir cell
cultures (HAE; Epithelix) of RG viruses based on A/195 with HA and NA from A/195 first-wave (blue) or HA and NA of A/687 third-wave (green triangle)
isolates. (d) A/687 (green square) or A/687 with A/687 with HA and NA from A/195 (blue triangle). Cells were infected at an MOI of 0.01. *, P  0.05 based on
an unpaired t test. (e) Mucus inhibition assay. An equal PFU of A/195 (blue) or A/195 with A/687 third-wave isolate NA (green) RG virus was incubated with
diluted human mucus for 1 h prior to infection of MDCK cells. Infectivity remaining was plotted as the percentage of the titer in the absence of mucus. *, P 
0.044 by unpaired t test.
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become infected, with possibly more efficient early virus replica-
tion, leading to more severe infections in some people.
A great deal of effort worldwide has been put into tracing
amino acid changes in the pandemic H1 HA, and to a lesser degree
the NA (28–37). This emphasis on the glycoproteins is under-
standable, due to their antigenic properties and importance in
determining antiviral susceptibility. Indeed, various functional
consequences of naturally occurring amino acid changes in the
NA and HA proteins have already been demonstrated using ani-
mal models (38–43). In our MOSAIC hospitalized cohort, we did
not detect the specific HA mutations described by others to affect
A(H1N1)pdm09 virulence, for example, HA D222G, which pur-
portedly facilitates better binding to -2,3-sialic acid-linked re-
ceptors in the lower respiratory tract (44–47), changes in glycosy-
lation (48), or antigenicity (49) were not present. Other groups
have suggested that HA D222G is relatively common in severe
cases (44–47).The D222G mutation has been suggested to some-
times arise during virus culture as an artifact and may also only be
present as a minority variant in samples taken at certain times
during the infection. We do not know why it was not detected in
our MOSAIC cohort.
We detected a different type of phenotypic change associated with
the HA protein of the third-wave viruses compared to the first-wave
isolate. A comparison of the viruses’ relative abilities to hemaggluti-
nate chicken, turkey, or guinea pig red blood cells indicated a relative
increase in affinity to -2,6-linked sialic acids and a concomitant
decrease in the ability to bind to -2,3-linked sialic acids for the ma-
jority of the third-wave isolates. This alone may have increased the
ability of the virus to infect the human upper respiratory tract, ac-
counting for the greater replication of A/687 in HAE cells. That the
lost affinity for the -2,3-sialic acids is observed in both second- and
third-wave isolates would implicate one or more of the previously
reported variations in the HA I32L, D97N, S185T, E374K, and S451N
(27). A recent publication by de Vries et al. (50) indicated a change in
receptor binding caused by an S185T mutation. We also note the
recent publication from Cotter et al. (51) showing that later isolates of
FIG 6 PA of third-wave virus confers enhanced polymerase activity and a fitness advantage in HAE cells. (a) Activities of polymerase reconstituted from plasmids
expressing polymerase components of A/195 first-wave (dark blue) and A/687 third-wave (dark green) viruses. 293T cells were transiently transfected with a
plasmid that directs in situ synthesis of a minigenome in which a luciferase reporter gene is flanked by the influenza A virus promoter. Cotransfection of a Renilla
expression plasmid was used to normalize for transfection efficiency. Combinations of the PB1, PB2, PA, and NP expression plasmids of A/195 (blue) or A/687
(green) or lacking the PB2 polymerase (white) were transfected. At 24 h posttransfection, cells were harvested. The results were normalized based on Renilla
results (transfection control) and are from three separate set of experiments, each with triplicate wells (n  9). Differences were analyzed using a one-way
ANOVA test with Tukey’s multiple-comparison test. (b) Human nasal MucilAir cell cultures (HAE; Epithelix) were infected in triplicate with RG viruses based
on A/195 that differed only in PA at N321K. Virus released was harvested at 24, 48, 72, and 96 h and sequenced using the Illumina system. The percentage of N
allele (first wave) is represented in blue and K (third wave) is shown in green.
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A(H1N1)pdm09 virus contained pH-stabilizing mutations in HA
which enhanced their replication in the ferret upper respiratory tract.
This mutation at HA residue E374K (H1 numbering) is present in 5
of 6 third-wave viruses in our subset (Table 1) and may also have
contributed to the increased replication in HAE cultures we observed
(Fig. 2b).
There may also be a contribution of NA to the increased
propagation of third-wave virus in HAE (Fig. 5c). All of the
second- and third-wave viruses in our cohort had NA muta-
tions V106I and N248D compared to first-wave A/195. These
are proposed to enhance viral stability, through modifications
in pH tolerance under acidic conditions, although we did not
assess this phenotype (52). However, we did observe an in-
crease in the ability of virus with third-wave NA to retain its
infectivity in human mucus, a property linked with efficient
replication in HAE cells and transmission in ferrets (23). Sev-
eral other research groups have already investigated variations
between individual isolates of the A(H1N1)pdm09 lineage.
These publications described a few selected isolates from mild,
severe, or fatal cases and characterized their phenotypes in var-
ious animal models without considering their broader phylo-
genetic relationships (41, 53–55). A correlation has sometimes
been observed between the outcome of infection in animal
models and the severity of the human case from which the
isolate was obtained; this was not the case in our study. Rather,
we found increased replication in primary human cells was
often accompanied by decreased virulence in the murine
model. It is well recognized that the mouse is not a good model
host for human-adapted influenza viruses.
Our work suggests that changes to internal viral proteins,
including NS1 and PA, occurred during evolution of the third-
wave viruses and adapted them for increased replication in
human cells. Others have also recently suggested that muta-
tions have occurred in the virus polymerase, since its transfer to
humans may enhance replication or transmission (56, 57).
These previously described mutations may contribute to some
of the enhanced polymerase activity we measured for the A/687
third-wave virus polymerase, but our in vitro polymerase re-
porter system also indicated that the N321K amino acid change
in the PA protein, not previously reported, drove enhancement
of viral polymerase activity. How it may achieve this is unclear.
PA is known to interact with host factors, such as transcrip-
tional modulator of RNA polymerase II (RNAPII) hCLE (58,
59) and the minichromosome maintenance complex (60). The
PA gene segment of A(H1N1)pdm09 virus was originally de-
rived from an avian source during the formation of the TRIG
internal gene cassette. Bussey et al. already described three
amino acids (85I, 186S, and 336M) present in the A(H1N1)
pdm09 PA that are not usually present in PA of avian viruses.
They concluded that these three mutations together may have
contributed to the ability of this polymerase complex to func-
tion better in mammalian cells. The mutation at residue 336 is
situated close to amino acid 321 on the crystal structure (61).
PA 321K was, until now, rare in swine-adapted influenza vi-
ruses, occurring in only 1.85% of sequences of all influenza virus A
subtypes and in 3% of swine H1N1 viruses before the emergence
of A(H1N1)pdm09 in 2009. It will be interesting to see if there is
an increase in the occurrence of a lysine at this position in swine as
the A(H1N1)pdm09 virus circulates in pigs or is reintroduced to
this host through contact with humans after the third wave. Only
2.06% of avian isolates have PA 321K. This amino acid does not
occur in the PA segment of seasonal human influenza viruses, but
the prevalence of the lysine variation in human isolates of pan-
demic H1N1 increased sharply as sequences from later in the pan-
demic were submitted to NCBI, supporting its prevalence during
and after the third wave. We expected the advantage conferred by
this single PA mutation engineered alone to be subtle, and there-
fore we analyzed the effect by using a competition assay rather
than by direct comparison of growth curves. Previously, we
showed that the NA mutation H275Y in first-wave virus conferred
a replicative cost that was not detected by growth curve analysis
but only by competition assay (62). Indeed, we found that virus
with the single PA change 321K outgrew 321N virus in 3 biological
replicates of HAE cultures. This type of fitness assay could be
useful in predicting the selection of mutations that confer subtle
advantage.
The other gene segment we investigated in detail here was that
which encodes the NS1 protein. Interestingly, we found a cluster
of mutations in NS1 that slightly enhanced its ability to control the
innate immune response, including IFN and other cytokines. In
the murine model, decreased virus titer in the lungs early in infec-
tion with third-wave viruses may also have contributed in part to
decreased IFN production. However, in human airway cultures
where third-wave virus replicated robustly, we observed decreased
IP-10 production in comparison with A/195. We attribute this to
changes in NS1, because other known antagonists of the inter-
feron response, such as PB1-F2, were not different between these
two viruses. Moreover, a 6:2 recombinant virus with HA and NA
from the third wave on a first-wave internal gene constellation
induced higher IP-10 and other cytokine responses in HAE cells
than whole first-wave virus (data not shown). This suggests that
the differences in cytokine response were not accounted for in this
case by changes in receptor binding specificity that affected cili-
ated versus nonciliated cell tropism in the HAE cultures, as sug-
gested by Ramos et al. in 2011 (63). One explanation for our find-
ings is that the NS1 protein had acquired some ability to bind to
host cell factor CPSF30 and inhibit host mRNA processing, a
mechanism by which other human-adapted influenza viruses
have enhanced their control of the human innate immune re-
sponse (64, 65). Indeed, exogenous expression of the A/687 NS1
gene inhibited the expression of a reporter gene from a polymer-
ase II promoter significantly more efficiently than the NS1 gene
from A/195 did (data not shown). This property is associated with
an ability to bind and inhibit CPSF30 and may account for the
difference we observed in heterologous control of induced inter-
feron (Fig. 4c). Hale et al. already predicted some mutations in
A/California/04/2009 virus by which this could be achieved, one
of which is common to the A/687 NS1, G189D (7). That study also
reported rather subtle effects on virus replication for viruses that
were engineered to have CPSF30 binding. Notably, one virus iso-
lated in the third wave, A/689, which phylogenetically lies closer to
second-wave viruses, was associated with higher cytokine levels
than other third-wave viruses in mouse lungs.
In conclusion, using a collection of A(H1N1)pdm09 viruses
chosen based on phylogenetic divergence, we have shown that
amino acid changes in HA, NA, NS1, and PA in later waves led to
functional changes in individual viral genes that conferred in-
creased replication in primary human airway cells, suggestive of
human adaptation. The increase in viral fitness overall may facil-
itate increased transmission, as suggested by Doriggati and Fergu-
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son, but the lack of viral genetic differences between severe and
community influenza cases suggests these changes are not on their
own sufficient to confer severe disease (16), especially as there is
evidence of high levels of asymptomatic or unreported illness dur-
ing the first three waves of A(H1N1)pdm09 virus activity in the
United Kingdom (12). Infection of those people predisposed to
more severe disease may have been more likely in the third wave
because of the differences in viral replication, host immune mod-
ulation, and viral persistence in the host and the external environ-
ment (66–68).
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